Amgen Aims To Submit NDA for PCSK9 Candidate During “Data-Rich” 2014
This article was originally published in The Pink Sheet Daily
The company now appears to be neck and neck with Regeneron in the race to market the first PCSK9 blocker for high cholesterol, with a filing possible by the end of the year. The drug is part of a deep late-stage pipeline, expected to yield pivotal data on numerous drugs by 2016.
You may also be interested in...
Emerging Markets Earnings Roundup: Amgen, Novartis (Part 3)
Amgen talked up its international expansion efforts while Novartis painted a picture of the growing importance of emerging markets to its bottom line. And both companies see biosimilars as a key play in emerging markets.
As Onyx Details Come Out, Amgen Turns To Biosimilars
Amgen is juggling both ends of its strategy, one focused on biosimilars and the other on new R&D-driven products. Further details have emerged about each, as Amgen tries to make the case it's a revenue growth story.
Amgen Wins Onyx, But Will The Deal Pave The Road To Transformation?
The addition of Onyx’s cancer drugs to Amgen’s portfolio will fill a near-term sales gap for the big biotech and reinforce the company as a major oncology player. But Amgen will need to execute expertly on the merger if it is to transform itself into a high-growth biotech.